Cardiometabolic Care resolves some of the greatest frustrations facing population health decision-makers, healthcare providers, and practice-based researchers committed to reducing all-cause mortality, comorbidities, and total cost of care (TCOC) in patients with complex, chronic conditions.
Cardiometabolic Care empowers these dedicated healthcare professionals to help patients plagued with cardiometabolic diseases (CMDs), comorbidities, and complications using highly reliable, efficient, and effective prevention, treatment, and mitigation strategies that rapidly resolve patient symptoms, improve their health, and enable them to be happier, more constructive members of their communities.
Cardiometabolic Care provides easy-to-integrate, unified clinical protocols and practice-transformation toolkits that enable those accountable for population health to…
- move beyond underperforming and administratively burdensome, conventional approaches to CMD management, and
- make extraordinary gains in all domains of the elusive Triple/Quadruple Aim—significantly reducing per capita costs, improving population health, and enhancing the experience of patients and providers.
Most healthcare professionals recognize that health is greatly influenced by environmental stimuli, personal beliefs, and genetics. What fewer realize is how these important health determinants interact and then modify epigenetics.
For example, cardiometabolic diseases strongly correlate with adverse circumstantial etiologies (ACEs).
Important ACEs include…
- adverse childhood experiences (e.g., violence, sexual abuse, and parental abandonment),
- adverse cultural exposures (e.g., ads for soft drinks, liquor, and cigarettes; sports-related concussions, conflict-related post-traumatic stress disorder [PTSD]), and
- adverse chemical effects (e.g., foods with high sugar, salt, and fat content; adverse drug reactions [ADRs]; and environmental pollutants such as pesticides).
ACEs are strongly correlated with CMD-exacerbating coping, compulsive, and addictive behaviors—and these can behaviors, in turn, are strongly correlated with a cascade of devasting health challenges.
Despite a rich body of science on the topic, few healthcare professionals understand how adverse circumstantial etiologies (e.g., ACEs such as adverse childhood experiences, adverse cultural exposures, and adverse chemical effects) correlate with cardiometabolic disease, CMD comorbidities, and death.
- ACEs influence coping, compulsive, and addictive behaviors.
- ACE-related dysfunctions expose the body to excessive oxidative particles.
- Oxidative particles correlate with changes in epigenetics.
- Epigenetic changes lead to an adverse molecular signaling cascade.
- Adverse metabolic signaling spirals into a disease-producing metabolic flywheel.
- The metabolic flywheel results in deadly psychosocial-physiological outcomes.
Cardiometabolic Care’s translational and practice-based research team has proven that a unified set of protocols and practice transformation toolkits can dramatically improve CMD prevention, treatment, and management—sidestepping, mitigating, or reversing the deadly effects of adverse stimuli, dysfunctional belief systems, maladaptive behaviors, oxidative particles, changes to epigenenics, epigenetically-driven molecular signaling cascades, and metabolic flywheels.
The thought and practice leaders behind Cardiometabolic Care are committed to closing the Institute of Medicine’s (IOM’s) estimated 17-Year Gap in translating overlooked scientific discoveries into practice. Through research on the environmental, belief-related, behavioral, epigenetic, and metabolic determinants of disease, the Cardiometabolic Care team created a portfolio of mutually reinforcing CMD-mitigating products, services, and solutions applicable in self-care, healthcare, and community care settings.
Cardiometabolic Care’s pioneering, translational CMD protocols and toolkits reflect new science, new systems, and new outcomes—all informed by critical discoveries in environmental medicine, epigenetics and molecular signaling, and biopsychosocial medicine.
Building on the largely overlooked base of epigenetically informed evidence, Cardiometabolic Care systematically improves population health. Our unified protocols and practice transformation toolkits empower primary care practices (PCPs) to succeed in an era of value-based contracting (VBC), outcomes-based contracting (OBC), and 360-degree impact accountability.
Cardiometabolic Care makes primary care practices (PCPs) more reliable, efficient, and effective.
Cardiometabolic Care also makes patients healthier through novel patient activation, engagement, and adherence strategies including culturally competent care, health plan navigation services, health literacy support services, and community care referral services (e.g., that address social determinants of health [SDoHs]).
Cardiometabolic Care’s new science underscores the importance of the ACE-activated psychosocial-physiological response, ACE-actuated epigenetics, and molecular medical management (MMM).
The Company’s new systems reflect value-based payment models, as well as impact-accountable training services, population health management programs, and business intelligence (BI) analytics solutions essential to clinical, administrative, and financial risk reduction.
Cardiometabolic Care’s new outcomes include unprecedented decreases in the incidence, prevalence, and cost of cardiometabolic diseases and other chronic conditions—leading to dramatically improved economic, clinical, and humanistic outcomes (ECHOs).
Informed by transdisciplinary, biopsychosocial research—and made possible by the latest scientific insight on epigenetic, translational, and precision medicine—Cardiometabolic Care’s unified protocols and toolkits help patients recover from CMDs and other chronic conditions with exceptional speed and remarkably low recurrence rates—all while dramatically reducing all-cause mortality, comorbidities, and total costs of care (TCOC).
That’s refreshing news for today’s most committed population health decision-makers, practice-based researchers, and care delivery teams—setting new standards for value-based cardiometabolic disease (CMD) management.
For more information, please contact us.